Long-term bortezomib treatment reduces allergen-specific IgE but fails to ameliorate chronic asthma in mice.
Int Arch Allergy Immunol
; 158(1): 43-53, 2012.
Article
in En
| MEDLINE
| ID: mdl-22212634
ABSTRACT
BACKGROUND:
Allergen-specific immunoglobulin (Ig) E initiates the effector cascade of allergic asthma and has been identified as a valuable target for therapeutic treatment of this disease. The proteasome inhibitor bortezomib was previously shown to deplete Ig-secreting plasma cells and to efficiently suppress Ig serum titers. The present study aimed at evaluating the therapeutic potential of the proteasome inhibitor bortezomib in allergic bronchial asthma.METHODS:
To address this question, a chronic experimental asthma mouse model was used in a therapeutic setting. Mice were sensitized to ovalbumin (OVA) and challenged with OVA aerosol for 12 weeks. After 6 weeks of challenge, bortezomib treatment was started and continued for 1 week (short-term) or 6 weeks (long-term) with a dosage of 0.75 mg/kg body weight twice a week. Lung function, lung histology, Ig serum titers and plasma cell numbers were assessed.RESULTS:
Whereas short-term treatment lowered bronchoalveolar lavage eosinophils, long-term treatment considerably reduced serum titers of anti-OVA IgE in mice with chronic experimental asthma. However, neither short-term nor long-term treatment significantly reduced plasma cell numbers, anti-OVA IgG1 serum titers or allergic airway inflammation or ablated airway hyperresponsiveness.CONCLUSION:
Our results suggest that bortezomib treatment has only limited value as plasma cell-depleting therapy against allergic bronchial asthma.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrazines
/
Asthma
/
Boronic Acids
/
Immunoglobulin E
/
Allergens
/
Anti-Asthmatic Agents
Limits:
Animals
Language:
En
Journal:
Int Arch Allergy Immunol
Journal subject:
ALERGIA E IMUNOLOGIA
Year:
2012
Document type:
Article